NEW YORK (GenomeWeb) — The Translational Genomics Research Institute (TGen) announced this week that it has been awarded a five-year grant worth $2 million from the National Institutes of Health to assess a blood-based method for monitoring metastatic melanoma.
The project — being led by TGen’s Muhammed Murtaza — aims to use circulating tumor DNA (ctDNA) to monitor drug response and resistance in metastatic melanoma patients in order to guide treatment decisions.
“To monitor melanoma during treatment, the only available test today is imaging, such as a CT scan,” Murtaza said in a statement. “But you can’t scan patients very often during treatment because it’s expensive and exposes patients to radiation. If we can develop a blood test to monitor treatment response, we may be able to use it weekly.”
With the NIH funding, Murtaza and collaborators will analyze serial plasma, tumor, and germline samples from metastatic melanoma patients from three cohorts: a completed anti-PD-1 immunotherapy trial; a collection from the Stand Up To Cancer Genomically Enabled Medicine for Melanoma trial; and a prospective observational study at Mayo Clinic Arizona that is evaluating standard of care immunotherapy and molecularly targeted drugs.
According to the grant’s abstract, the investigators will use